ValiRx plc (LON:VAL – Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as GBX 0.71 ($0.01) and last traded at GBX 0.72 ($0.01), with a volume of 2828047 shares trading hands. The stock had previously closed at GBX 0.75 ($0.01).
ValiRx Trading Up 1.4 %
The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The company has a market cap of £972,772.50, a price-to-earnings ratio of -35.50 and a beta of 0.59. The firm has a 50 day moving average price of GBX 1.46 and a two-hundred day moving average price of GBX 2.05.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Articles
- Five stocks we like better than ValiRx
- CD Calculator: Certificate of Deposit Calculator
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Trading Halts Explained
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Where to Find Earnings Call Transcripts
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
